India · Delayed Price · Currency is INR Akums Drugs and Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
FY 2026 saw resilient growth with revenue up 5.8% and strong CDMO performance, despite API headwinds. International expansion accelerated with major contracts in Europe and Zambia, while cash flow and liquidity remained robust. CapEx and dividend plans support future growth.
-
Q3 FY26 saw robust revenue and EBITDA growth, led by strong CDMO and international branded formulation performance, with margin expansion and improved cash flows. Key projects in Europe and Zambia are progressing, and automation initiatives are underway.
-
Revenue declined 1.5% YoY to INR 1,018 crore in Q2 FY 2026, with EBITDA margin dropping to 9.3% due to API price declines and new facility overheads. Strategic initiatives include a Zambia JV and a major European CDMO contract, with strong cash reserves supporting future growth.
-
Revenue and profitability grew in Q1 FY26, led by CDMO and R&D milestones, despite API price declines. Cash position is strong, with a EUR 100 million EU contract advance and robust free cash flow. Mid single-digit growth is targeted for FY26, with European expansion underway.
Fiscal Year 2025
-
FY 2025 saw flat annual revenue amid API price erosion and muted volumes, but Q4 delivered double-digit growth in both revenue and EBITDA. Strong cash flows, a major European contract, and robust international expansion position the company for high single-digit volume growth and margin stability in FY 2026.
-
Secured a EUR 200 million European CDMO contract with commercial supply starting 2027 and received an upfront payment. Q3 EBITDA grew 12% year-over-year despite a 6% revenue decline, with strong CDMO margins and improved free cash flow. API losses narrowed, with break-even targeted in 1–2 years.
-
Q2 FY25 revenue rose 2% sequentially but fell 10% YoY, with EBITDA margin at 12.9% due to lower demand and API price declines. CDMO remains the main revenue driver, while export and R&D investments continue. API business faces margin pressure, but new facilities and international expansion are expected to support future growth.
-
Revenue grew 5.1% year-over-year to INR 1,019 crores, with strong 14% CDMO volume growth and improved margins despite API price declines. New capacity expansions and global dossier approvals support future growth, while debt reduction and positive cash flow strengthen the balance sheet.